SCHEMBL257309

SCHEMBL257309

Cc1nn2c(-c3ccc(F)c(F)c3)cc(Cl)nc2c1I

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
MAPT P10636 6/20 0.36
ALDH1A1 P00352 4/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
NTRK1 P04629 3/20 0.34
PIM1 P11309 3/20 0.34
ACVR1 Q04771 2/20 0.34
POLB P06746 1/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 3/20 0.34
NPC1 O15118 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPK1 P28482 2/20 0.33
HSD17B10 Q99714 1/20 0.33
KCNH2 Q12809 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257314 0.87 TP53 (0.41) TP53MAPTALDH1A1KMT2AMEN1
SCHEMBL15020811 0.83 TP53 (0.43) TP53MAPTALDH1A1KMT2AKDM4E
SCHEMBL257700 0.83 TP53 (0.34) TP53MAPTALDH1A1KMT2APOLB
SCHEMBL257519 0.81 MAPT (0.40) TP53MAPTALDH1A1KMT2APOLB
SCHEMBL15020909 0.78 PDE10A (0.34) TP53
SCHEMBL10072287 0.75 TP53 (0.46) TP53MAPTALDH1A1KMT2AMEN1
SCHEMBL21177370 0.73 MAPT (0.45) TP53MAPTALDH1A1KMT2AMEN1
SCHEMBL15020911 0.72 FPR2 (0.41) NTRK1
SCHEMBL257382 0.69 TP53 (0.53) TP53MAPTALDH1A1KMT2AMEN1
SCHEMBL10072008 0.68 TP53 (0.52) TP53MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 TP53 4550/4885MAPT 2617/4885ALDH1A1 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.